Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in J Hypertens

Retrieve available abstracts of 56 articles:
HTML format



Single Articles


    February 2021
  1. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.
    J Hypertens. 2021 Feb 3. pii: 00004872-900000000-96717.
    PubMed     Abstract available


    January 2021
  2. SARAFIDIS P, Ortiz A, Ferro CJ, Halimi JM, et al
    Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
    J Hypertens. 2021 Jan 11. pii: 00004872-900000000-96744.
    PubMed     Abstract available


    December 2020
  3. ANDERSSON T, Pikkemaat M, Schioler L, Hjerpe P, et al
    Country of birth and mortality risk in hypertension with and without diabetes: the Swedish primary care cardiovascular database.
    J Hypertens. 2020 Dec 5. doi: 10.1097/HJH.0000000000002744.
    PubMed     Abstract available


  4. SHAH P, Owens J, Franklin J, Jani Y, et al
    Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients.
    J Hypertens. 2020;38:2537-2541.
    PubMed     Abstract available


    November 2020
  5. CARDOSO CRL, Salles GC, Leite NC, Salles GF, et al
    Prognostic impact of short-term ambulatory blood pressure variability for microvascular and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.
    J Hypertens. 2020 Nov 24. doi: 10.1097/HJH.0000000000002710.
    PubMed     Abstract available


  6. PAPADOPOULOU E, Loutradis C, Tzatzagou G, Kotsa K, et al
    Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
    J Hypertens. 2020 Nov 11. doi: 10.1097/HJH.0000000000002690.
    PubMed     Abstract available


    October 2020
  7. JIANG L, Ren Y, Yu H, Guo YK, et al
    Additive effect of hypertension on left ventricular structure and function in patients with asymptomatic type 2 diabetes mellitus.
    J Hypertens. 2020 Oct 6. doi: 10.1097/HJH.0000000000002643.
    PubMed     Abstract available


    August 2020
  8. VOLPE M, Gallo G
    Systolic blood pressure target less than 120 mmHg: the 'Chariot Allegory' in hypertension?
    J Hypertens. 2020;38:1462-1463.
    PubMed    


    July 2020
  9. SAVOIA C, De Ciuceis C, Paini A, Carletti R, et al
    Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.
    J Hypertens. 2020 Jul 27. doi: 10.1097/HJH.0000000000002595.
    PubMed     Abstract available


  10. VIAZZI F, Russo E, Mirijello A, Fioretto P, et al
    Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes.
    J Hypertens. 2020 Jul 6. doi: 10.1097/HJH.0000000000002543.
    PubMed     Abstract available


    June 2020
  11. BOHM M, Fitchett D, Ofstad AP, Brueckmann M, et al
    Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
    J Hypertens. 2020 Jun 25. doi: 10.1097/HJH.0000000000002492.
    PubMed     Abstract available


  12. VAN BOMMEL EJM, Smits MM, Ruiter D, Muskiet MHA, et al
    Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
    J Hypertens. 2020 Jun 6. doi: 10.1097/HJH.0000000000002480.
    PubMed     Abstract available


    May 2020
  13. CONTRERAS G, Lu L, Tamariz L, Rocco MV, et al
    Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial.
    J Hypertens. 2020 May 7. doi: 10.1097/HJH.0000000000002437.
    PubMed     Abstract available


  14. GRASSI G, Biffi A, Dell'Oro R, Quarti Trevano F, et al
    Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis.
    J Hypertens. 2020 May 7. doi: 10.1097/HJH.0000000000002431.
    PubMed     Abstract available



  15. Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes: Erratum.
    J Hypertens. 2020;38:980.
    PubMed    


    April 2020
  16. RADAELLI MG, Ciardullo S, Perra S, Cannistraci R, et al
    Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease.
    J Hypertens. 2020 Apr 3. doi: 10.1097/HJH.0000000000002443.
    PubMed     Abstract available


  17. BERBARI AE
    Angiotensin receptor neprolysin inhibitors: a novel approach to prevent cardiorenal disease in diabetes mellitus.
    J Hypertens. 2020;38:608-609.
    PubMed    


    February 2020
  18. MEYER ML, Klein BE, Klein R, Palta P, et al
    Central arterial stiffness and retinal vessel calibers: the Atherosclerosis Risk in Communities Study-Neurocognitive Study.
    J Hypertens. 2020;38:266-273.
    PubMed     Abstract available


    December 2019
  19. UIJL E, 't Hart DC, Roksnoer LCW, Clahsen-van Groningen MC, et al
    Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    J Hypertens. 2019 Dec 4. doi: 10.1097/HJH.0000000000002326.
    PubMed     Abstract available


    November 2019
  20. KOTSIS V, Jordan J, Stabouli S, Antza C, et al
    Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.
    J Hypertens. 2019 Nov 20. doi: 10.1097/HJH.0000000000002279.
    PubMed     Abstract available


    September 2019
  21. HOLTROP J, Spiering W, Nathoe HM, De Borst GJ, et al
    Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus.
    J Hypertens. 2019 Sep 19. doi: 10.1097/HJH.0000000000002227.
    PubMed     Abstract available


    August 2019
  22. VALLEE A, Olie V, Lelong HEL, Kretz S, et al
    Relationship between BMI and aortic stiffness: influence of anthropometric indices in hypertensive men and women.
    J Hypertens. 2019 Aug 23. doi: 10.1097/HJH.0000000000002228.
    PubMed     Abstract available


    July 2019
  23. PIPERIDOU A, Sarafidis P, Boutou A, Thomopoulos C, et al
    The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    J Hypertens. 2019;37:1334-1343.
    PubMed     Abstract available


    June 2019
  24. CIFKOVA R, Lanska V, Bruthans J, Mayer O Jr, et al
    Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registr
    J Hypertens. 2019 Jun 24. doi: 10.1097/HJH.0000000000002130.
    PubMed     Abstract available


    May 2019
  25. THOMOPOULOS C, Bazoukis G, Ilias I, Tsioufis C, et al
    Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    J Hypertens. 2019 May 30. doi: 10.1097/HJH.0000000000002152.
    PubMed     Abstract available


  26. HEAD GA, Shaw JE, Dunstan DW, Owen N, et al
    Hypertension, white-coat hypertension and masked hypertension in Australia: findings from the Australian Diabetes, Obesity, and Lifestyle Study 3.
    J Hypertens. 2019 May 1. doi: 10.1097/HJH.0000000000002087.
    PubMed     Abstract available


    April 2019
  27. VUKOMANOVIC V, Suzic-Lazic J, Celic V, Cuspidi C, et al
    The relationship between functional capacity and left ventricular strain in patients with uncomplicated type 2 diabetes.
    J Hypertens. 2019 Apr 29. doi: 10.1097/HJH.0000000000002125.
    PubMed     Abstract available


  28. SENANAYAKE S, Ruwanpathirana T, Gunawardena N
    Hypertension in a rural community in Sri Lanka: prevalence, associated factors and its effect on the renal profile.
    J Hypertens. 2019 Apr 15. doi: 10.1097/HJH.0000000000002107.
    PubMed     Abstract available


  29. NAGAI M, Dote K, Kato M, Oda N, et al
    Visit-to-visit blood pressure variability and a risk of diabetic foot ulcers: how calcium channel blockers moderate?
    J Hypertens. 2019;37:860-861.
    PubMed    


  30. VIAZZI F, Bonino B, Mirijello A, Fioretto P, et al
    Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes.
    J Hypertens. 2019;37:805-813.
    PubMed     Abstract available


  31. ZHANG Z, Tremblay J, Raelson J, Sofer T, et al
    EPHA4 regulates vascular smooth muscle cell contractility and is a sex-specific hypertension risk gene in individuals with type 2 diabetes.
    J Hypertens. 2019;37:775-789.
    PubMed     Abstract available


    March 2019
  32. LOPEZ-JARAMILLO P, Barbosa E, Molina DI, Sanchez R, et al
    Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
    J Hypertens. 2019 Mar 14. doi: 10.1097/HJH.0000000000002072.
    PubMed     Abstract available


  33. SARMA AV, Hotaling JM, de Boer IH, Dunn RL, et al
    Blood pressure, antihypertensive medication use, and risk of erectile dysfunction in men with type I diabetes.
    J Hypertens. 2019 Mar 14. doi: 10.1097/HJH.0000000000001988.
    PubMed     Abstract available


    February 2019
  34. DRIESSEN JHM, de Vries F, van Onzenoort HAW, Schram MT, et al
    Metformin use in type 2 diabetic patients is not associated with lower arterial stiffness: the Maastricht Study.
    J Hypertens. 2019;37:365-371.
    PubMed     Abstract available


    January 2019
  35. YU ZB, Li D, Chen XY, Lin HB, et al
    Prognostic value of visit-to-visit systolic blood pressure variability related to diabetic kidney disease among patients with type 2 diabetes.
    J Hypertens. 2019 Jan 11. doi: 10.1097/HJH.0000000000002038.
    PubMed     Abstract available


  36. VIAZZI F, Bonino B, Mirijello A, Fioretto P, et al
    Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes.
    J Hypertens. 2019 Jan 7. doi: 10.1097/HJH.0000000000001950.
    PubMed     Abstract available


  37. HAN X, McCombs J, Chu M, Dougherty JS, et al
    Impact of early initiation of antihypertensive medications for patients with hypertension or elevated blood pressure.
    J Hypertens. 2019 Jan 7. doi: 10.1097/HJH.0000000000002014.
    PubMed     Abstract available


    December 2018
  38. COOPER ME, Perkovic V, Groop PH, Hocher B, et al
    Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
    J Hypertens. 2018 Dec 11. doi: 10.1097/HJH.0000000000002032.
    PubMed     Abstract available


    November 2018
  39. PALATINI P
    Risk of developing foot ulcers in diabetes: contribution of high visit-to-visit blood pressure variability.
    J Hypertens. 2018;36:2132-2134.
    PubMed    


    October 2018

  40. Albuminuria and diabetes: a question of eye and skin points of view: Erratum.
    J Hypertens. 2018;36:2121.
    PubMed    


    August 2018
  41. RAMIREZ AJ, Sanchez MJ, Sanchez RA
    Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril.
    J Hypertens. 2018 Aug 14. doi: 10.1097/HJH.0000000000001907.
    PubMed     Abstract available


    July 2018
  42. LEE CJ, Hwang J, Lee YH, Oh J, et al
    Blood pressure level associated with lowest cardiovascular event in hypertensive diabetic patients.
    J Hypertens. 2018 Jul 13. doi: 10.1097/HJH.0000000000001842.
    PubMed     Abstract available


  43. VALLEE A, Yannoutsos A, Temmar M, Dreyfuss Tubiana C, et al
    Determinants of the aortic pulse wave velocity index in hypertensive and diabetic patients: predictive and therapeutic implications.
    J Hypertens. 2018 Jul 10. doi: 10.1097/HJH.0000000000001828.
    PubMed     Abstract available


    May 2018
  44. BRENNAN MB, Guihan M, Budiman-Mak E, Kang H, et al
    Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers.
    J Hypertens. 2018 May 22. doi: 10.1097/HJH.0000000000001783.
    PubMed     Abstract available


  45. LIU J, Yasuno S, Oba K, Konda M, et al
    Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
    J Hypertens. 2018 May 9. doi: 10.1097/HJH.0000000000001780.
    PubMed     Abstract available


  46. VIRDIS A, Masi S, Grassi G
    Albuminuria and diabetes: a question of eye and skin points of view.
    J Hypertens. 2018;36:1036-1037.
    PubMed    


    April 2018
  47. VIAZZI F, Ceriello A, Fioretto P, Giorda C, et al
    Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension: a real-life observational study.
    J Hypertens. 2018 Apr 19. doi: 10.1097/HJH.0000000000001749.
    PubMed     Abstract available


  48. KOTSIS V, Tsioufis K, Antza C, Seravalle G, et al
    Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease
    J Hypertens. 2018 Apr 12. doi: 10.1097/HJH.0000000000001731.
    PubMed     Abstract available


  49. KOTSIS V, Jordan J, Micic D, Finer N, et al
    Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hyperten
    J Hypertens. 2018 Apr 9. doi: 10.1097/HJH.0000000000001730.
    PubMed     Abstract available


    March 2018
  50. BOMBELLI M, Quarti-Trevano F, Tadic M, Facchetti R, et al
    Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study.
    J Hypertens. 2018 Mar 14. doi: 10.1097/HJH.0000000000001721.
    PubMed     Abstract available


    January 2018
  51. EGUCHI K, Hoshide S, Kario K
    Target home morning SBP be below 125 mmHg in type 2 diabetes patients.
    J Hypertens. 2018 Jan 23. doi: 10.1097/HJH.0000000000001683.
    PubMed     Abstract available


  52. YANNOUTSOS A, Bahous SA, Safar ME, Blacher J, et al
    Clinical relevance of aortic stiffness in end-stage renal disease and diabetes: implication for hypertension management.
    J Hypertens. 2018 Jan 2. doi: 10.1097/HJH.0000000000001665.
    PubMed     Abstract available


  53. ZHANG Y, Jiang X, Bo J, Yin L, et al
    Risk of stroke and coronary heart disease among various levels of blood pressure in diabetic and nondiabetic Chinese patients.
    J Hypertens. 2018;36:93-100.
    PubMed     Abstract available


  54. AHMAD A, Oparil S
    What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?
    J Hypertens. 2018;36:37-40.
    PubMed    


    December 2017
  55. USHIGOME E, Matsumoto S, Oyabu C, Kitagawa N, et al
    Prognostic significance of day-by-day variability of home blood pressure on progression to macroalbuminuria in patients with diabetes.
    J Hypertens. 2017 Dec 27. doi: 10.1097/HJH.0000000000001657.
    PubMed     Abstract available


  56. BEUSCHLEIN F, Reincke M, Arlt W
    The impact of Connshing's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk.
    J Hypertens. 2017;35:2548.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: